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Abstract
Introduction: A variety of national and international guidelines exist around the management of carbapenem
resistant Enterobacteriaceae (CREs), but some of these are several years old and do not reflect current epidemiology
and they also do not necessarily give pragmatic advice around active surveillance of CREs in countries with a high
burden of cases and limited resources. This paper aims to provide a best practice position paper to guide active
surveillance in a variety of scenarios in these settings, and discusses which patients should be screened, what
methods could be used for screening, and how results might influence infection prevention interventions.
Methods: This paper was developed as a result of a series of meetings of expert opinion leaders representing the
major infectious disease and infection prevention societies in Italy and having the endorsement of AMCLI (Italian
Association of Clinical Microbiology) and SITA (Italian Society for Anti-infective Therapy). There was no attempt to
undertake a full systematic review of the evidence, as it was felt that this was inadequate to inform a pragmatic
view on the best way forward based on current epidemiology and infection rates.
Key recommendations: Key recommendations focus on the urgent need to promote measures to prevent
transmission and infection, focusing on high risk patients and clinical areas, as well as outbreak situations. Active
surveillance leading to appropriate infection prevention precautions plays a major role in this.
Conclusions: There are limited national or international guidelines giving pragmatic advice on the most appropriate
measures for active surveillance and management of colonized patients in a high-burden setting such as Italy. While
individual hospitals and regions will need to formulate their own policies based on local epidemiology, this position
paper attempts to highlight current best practice in this area and provide pragmatic advice for clinicians, infection
prevention staff, and healthcare managers.
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Background
Aims and target groups
The purpose of this paper was to address practical ques-
tions for clinicians, infection prevention and control
(IPC) practitioners, and diagnostic laboratory personnel
dealing with the screening of carbapenem-resistant
Enterobacteriaceae (CRE) carriage in healthcare settings
from areas of high CRE endemicity, in view of the frag-
mentation in the observational literature on this topic
and the lack of randomized clinical trials.
Methods
A review of the current literature regarding the situation
with CRE in Europe, with a focus on Italy as an area of
high endemicity, and of the current laboratory methods
for screening for CRE carriage, were undertaken. Subse-
quently, a panel of seven experts developed a list of
questions to be addressed in the paper, with three ques-
tions being formulated after three rounds of discussion
among panel members. In view of the lack of strong evi-
dence, panel members were asked to provide narrative
answers on the basis of their knowledge and experience
in the field. Finally, answers were reviewed and discussed
by the panel, until a consensus was reached.
CRE: definitions and mechanisms
CRE are among the most challenging antibiotic-resistant
pathogens emerged in the clinical setting, due to their
ability to spread rapidly in healthcare environments and
to cause infections associated with high morbidity and
mortality, for which very limited treatment options are
available [1].
At least two different mechanisms can be responsible
for the carbapenem-resistant phenotype of CRE strains,
including: i) decreased outer membrane permeability in
combination with the overproduction of β-lactamases
with marginal carbapenem-hydrolyzing activity (e. g.
some AmpC-type or extended-spectrum β-lactamases);
and ii) the production of β-lactamases with efficient
carbapenemase activity (carbapenemases). The former
mechanism is dependent on chromosomal mutations:
mutants are usually selected under carbapenem treat-
ment and encountered sporadically or causing small out-
breaks, and usually exhibit only a moderate increase of
carbapenem minimum inhibitory concentration (MIC)
[2]. Carbapenemase production is due to the horizontal
acquisition of one or more mobile carbapenemase genes
(usually plasmid-borne) and is the most prevalent and
epidemiologically relevant resistance mechanism. In fact,
in settings of high CRE prevalence, carbapenemase-pro-
ducing Enterobacteriaceae (CPE) usually contribute the
majority of CRE isolates from clinical sources [3].
The relationship between CRE and CPE is one of
broad but not complete overlapping, since most but not
all CRE are CPE and vice versa. In fact, some CRE are
not CPE (i. e. those with a carbapenem resistance mech-
anism other than carbapenemase production) and some
CPE are not CRE (i. e. those which exhibit low carba-
penem MICs and remain phenotypically susceptible to
carbapenems).
Several different carbapenemases can be encountered
among CPE, including class A serine β-lactamases (e. g.
KPC-type enzymes), class D serine β-lactamases (e. g.
OXA-48 and related enzymes) and class B metallo-β-lacta-
mases (e. g. NDM-, VIM- and IMP-type enzymes). Carba-
penemases of different classes exhibit different functional
properties, which may be relevant to their phenotypic de-
tection (e. g. KPC enzymes are inhibited by boronic acids
but not by EDTA and can be detected by synergy testing
using these inhibitors) and to clinical treatment (e. g. KPC
enzymes are inhibited by the new β-lactamase inhibitors
avibactam and vaborbactam, while this is not the case for
the metallo-β-lactamases) [4].
Diversity of CRE epidemiology in Europe, and the Italian
perspective
In Europe, CRE have been reported from most coun-
tries, although with variable prevalences. In many coun-
tries the overall prevalence remains low, with most cases
being related to cross-border transfer followed by occa-
sional outbreaks. However, in a few European countries
(e. g. Greece, Italy, Romania) CRE have experienced a
massive dissemination leading to a condition of high-
level endemicity, while in some other countries (e. g.
Spain, Portugal, Bulgaria) the prevalence of CRE is lower
but reported on the increase. The epidemiological diver-
sity among different European countries does not only
concern the overall prevalence of CRE but also the type
of prevalent carbapenemases among CPE, as shown by
the results of the recent EuSCAPE survey [5].
Italy has been among the first European countries to re-
port the isolation of CPE from clinical specimens [6, 7],
and is one among the countries which have experienced a
rapid and massive dissemination of CRE since 2010. In
Italy, this CRE epidemic has mostly been contributed by
the dissemination of Klebsiella pneumoniae strains produ-
cing KPC-type carbapenemases (KPC-Kp), while CRE
strains producing other carbapenemases or those not pro-
ducing carbapenemases have remained relatively uncom-
mon [8, 9]. In particular, despite their earlier emergence,
VIM producers have remained sporadic or at most were
associated with small outbreaks. On the other hand,
strains producing NDM-type or OXA-48-like carbapene-
mases were reported more recently, as sporadic cases or
causing small outbreaks, usually associated with cross-
border importation [10–14]. Recent nationwide surveil-
lance data show that KPC represents 95% of carbapenem
resistance genes in E.coli and K pneumoniae strains
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isolated from bloodstream infections [15]. This epidemio-
logical scenario is different from that of other European
countries of high CRE endemicity. For instance, Greece
experienced a remarkable diffusion of VIM-producing
strains since the early 2000s, and thereafter this scenario
was compounded by the superimposition/partial replace-
ment with KPC-Kp and, more recently, also with OXA-
48-producers [16, 17].
In Italy, the CRE epidemic started since 2010 rapidly
expanded at a countrywide level, and CRE are currently
encountered not only among inpatients from acute-care
hospitals but also among outpatients [18] and patients
from long-term-care facilities [19, 20]. Reported preva-
lences of CRE carriage were variable in different settings,
also reflecting different patient populations, screening
strategies and study periods. Prevalences ranging from
0.2 to 3.9% were reported among inpatients from acute
care hospitals in northern Italy, at the beginning of the
CRE epidemic [21, 22]. Very high rates of CRE carriage
(28.4%) were recently reported among patients from a
long-term acute-care rehabilitation facility (LTACRF) in
central Italy [20], underscoring the role that LTACRF
can play in the dissemination of CRE in endemic areas.
The burden of CRE
The archetype of a CRE target is a patient affected by
many comorbidities, with a history of repeated hospital
admissions, long hospital stay and undergoing relevant
management complexities. Consequently, the higher the
complexity of the care pathway and the fragility of the
patient, the greater the likelihood of CRE colonization
and subsequent invasive disease [23]. Regarding invasive
diseases, bacteremia, pneumonia and surgical site infec-
tions are an increasingly complex challenge in relation
both to the predicted poor patient clinical status and
scanty therapeutic options [24, 25].
In a recent meta-analysis, an overall 16.5% risk of infec-
tion with CRE amongst patients colonized with CRE has
been suggested [26]. However, rates of infection reported
in individual studies varied widely, from 0 to 89%, mainly
in relation to case mix and comorbidities, with the major-
ity falling in the range of 7.6–44.4% [27, 28].
In colonized patients, chemotherapy for acute leukemia,
solid organ transplantation, and ICU stay represent the
most important patient-related conditions associated with
a significant risk of CRE infections [29]. Likewise, pro-
longed exposure to broad spectrum antibiotics and pres-
ence of central venous catheters are the main modifiable
variables involved. A recently published case-control study
of long-term acute care hospitals (LTACH) patients found
that independent factors associated with CRE colonization
and infection in this setting included solid organ and stem
cell transplantation, mechanical ventilation, fecal incontin-
ence, and exposure in the prior 30 days to carbapenems,
vancomycin, and metronidazole [30]. Finally, CPE are as-
sociated with considerable mortality, and they may be
more virulent than non-carbapenemase-producing CRE
and are associated with poorer outcomes [31].
Costs of the diseases sustained by multidrug resistant
(MDR) pathogens are well known [32, 33]. Of particular
concern is the clinical and economic impact of MDR
gram-negative bacilli because of the substantial changes
in workflow and processes required [34]. Moreover, in
the case of CRE, costs could be higher than with other
resistant Gram-negative bacteria because they are more
difficult to treat and need more extensive prevention
and aggressive control activities. Indeed, many elements
contribute to the real costs associated with the control
of infections and colonization supported by CRE. These
include the costs associated with the need for increased
surveillance within each hospital to determine which path-
ogens are problematic by patient type and hospital care.
The first steps to control the spread of CRE infection
consist of implementing a multimodal strategy for the
management of carriage, including early identification,
contact precautions, patient isolation, hand and environ-
mental hygiene, and antimicrobial stewardship (see below).
This strategy directed at interrupting cross-transmission, is
considered the most cost-effective in any economic ana-
lysis regarding multidrug resistant organisms (MDRO). A
recently published review [35] has noticed that the costs
calculation is highly variable across published studies,
mainly because of the high heterogeneity in methods,
organism, involved country and hospital.
Recently, an estimate of the costs associated with an
outbreak of carbapenemase-producing Enterobacteria-
ceae (CPE) was performed during an outbreak of New
Delhi metallo-beta–lactamase producing Klebsiella
pneumoniae in a group of five hospitals in London, with
approximately 1500 beds and 190,000 admissions per
year. Costs associated with the outbreak were split into
actual expenditure (enhanced and enlarged screening activ-
ities, additional infectious disease consultant time, expend-
iture for antimicrobials, contact precautions, isolation
costs, monitoring of hand washing, environmental decon-
tamination, potential bed closures) and ‘opportunity cost’
(including additional staffing time, missed revenue and
extended length of hospital stay). The overall expenses
related to the outbreak were around € 1.1 million
over 10 months (range 0.9–1.4 million), composed of
€ 312,000 for actual expenditure, and € 822,000
(range 631,000–1.1 m) for opportunity cost [36].
The Centers for Disease Control and Prevention have de-
veloped a CRE clinical and economic outcomes model to
determine the cost of CRE related disease, by infection site
including bloodstream infections, pneumonia (ventilator as-
sociated or not), complicated intra-abdominal infections
and complicated urinary tract infections. Costs were
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considered from a hospital, a third-party payer and a social
perspective. The first included costs related to the add-
itional length of stay attributable to CRE infection, the sec-
ond consisted of direct costs for hospitalization, treatment
and associated diagnostic tests, while the social perspective
included direct and indirect (i.e. productivity losses and
mortality) costs. Taken as a whole the cost for every case
could be quantified as up to 181,164 USD depending on in-
fection type, contributed by up to 66,031 USD for the hos-
pital, up to 31,621 USD for third-party payers, and up to
83,512 USD for society [37].
It is therefore evident that the cost of CRE infections is
higher than the annual cost of many chronic diseases and
of many acute diseases, and these could further increase if
we consider the rising legal expenses, related to lawsuits.
Given the growing epidemiological threat in Italy, as in
several other European countries, investment in preven-
tion and control are urgent as well as mandatory.
Control strategies for CRE, and roles of active screening
for detection of CRE carriage
In 2013 a group of experts under the auspices of the
European Society of Clinical Microbiology and Infec-
tious Diseases (ESCMID) performed a systematic review
of the articles published on IPC measures for preventing
the spread of multidrug-resistant organisms in the
healthcare setting, in order to determine their effective-
ness and to define the indication for application for spe-
cific types of resistant strains [38]. Moreover, IPC
measures were studied according to the epidemiological
setting, i.e. endemic or epidemic. An endemic setting
was defined as a setting where there are constant chal-
lenges from admission of patients colonized or infected
by multidrug-resistant organisms. An epidemic setting
was defined as a setting with an unexpected increase of
cases of infection by multi-drug resistant organisms or
emergence of new strains not previously isolated in that
setting. The GRADE methodology was applied for
defining quality of evidence and strength of recommen-
dations. Eighty-six studies from 1981 to 2011 were in-
cluded in the final analysis. The main IPC measures and
other strategies that were evaluated included hand
hygiene, contact precautions, active screening cultures, en-
vironmental cleaning, antimicrobial stewardship, decol-
onization, and infrastructure and education. Both in
endemic and in epidemic settings, implementation of hand
hygiene education programmes was considered a strong
recommendation to reduce the transmission of ESBL-pro-
ducing Enterobacteriacae and multidrug-resistant gram
negative organisms, with different levels of evidence from
moderate to very low. The effectiveness of contact precau-
tions for preventing the transmission of multidrug resistant
Gram-negative organisms is controversial. In the epidemic
setting there is a strong recommendation for implementing
contact precautions for all colonized and/or infected pa-
tients. Moreover, there is a strong recommendation for
using alert codes to identify known colonized patients at
admission and perform screening and pre-emptive contact
precaution. Isolation in a single room both for colonized
and infected patients represents a strong recommendation
together with cohort staffing (only for MDR- K. pneumo-
niae). In the endemic setting, implementation of contact
precautions for patients colonized with MDR resistant
gram negative organisms represents a strong recommenda-
tion. Regarding one of the more controversial points in
everyday practice, i.e. the active screening for detection of
CRE carriage, in the epidemic setting the ESCMID guide-
lines strongly recommend the implementation of active
screening for the main resistant gram negative pathogens
at hospital admission followed by contact precautions; re-
garding the endemic setting, due to lack of evidence, active
screening should be suggested only as an additional meas-
ure. Monitoring cleaning performance to ensure proper
environmental cleaning represents a strong recommenda-
tion both in the epidemic and in the endemic setting.
Finally, antimicrobial stewardship and education are also
strongly recommended in both settings.
A following article evidenced some controversies in
the recommendations from various sources, including
ESCMID, Irish, English, Scottish and ECDC guidelines
reflecting the poor quality of the evidence base. These
controversies include when to apply contact precautions,
single room isolation, active screening culture, staff and
patient cohorting, healthcare workers’ screening, patient
decolonization and environmental cleaning [39].
In 2016 ECDC published documents on the rapid risk as-
sessment of carbapenem-resistant Enterobacteriaceae and
Acinetobacter baumannii in healthcare settings [40, 41].
The main options for actions to reduce identified risks in-
cluded proper and timely clinical management, infection
prevention and control measures in hospital and other
healthcare settings, active screening in the epidemic set-
ting and active surveillance in the endemic one, and anti-
microbial stewardship. For CRE, a major emphasis was
given to targeting patients at high risk for carriage of CRE,
i.e. patients who had recently been hospitalised in a coun-
try or a region known as having a high CRE prevalence, or
who were transferred from a hospital with high CRE
prevalence. These patients should be screened for CRE di-
gestive tract carriage and pre-emptive contact precautions
and isolation should be considered.
The report from ECDC concerning the effectiveness of
infection control measures to prevent transmission of
CPE stated that no study assessed screening/surveillance
as a single intervention, but the authors concluded that
there is evidence to suggest that active rectal screening/
surveillance on admission to hospital or a specific ward
and during an outbreak can effectively limit and prevent
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the spread of CPE. The ECDC document recognizes,
among other most effective interventions, patient isola-
tion, patient cohorting and application of contact precau-
tions. All these measures are usually applied when a
patient is diagnosed as colonized and/or infected by CPE.
In Italy, the first agency to produce a document for
the control of CRE was the Region Emilia Romagna in
2012 [42]. The infection control measures recommended
to the healthcare settings in the region included pheno-
typic confirmation of carbapenemase production, active
surveillance of asymptomatic carriers and contact isola-
tion precautions for carriers. Surveillance of asymptom-
atic carriers was performed by rectal swabs for close
contacts of hospitalised patients with CPE (patients stay-
ing in the same hospital unit), high-risk patients at
hospital admission (i.e. patients transferred from other
acute hospitals and LTCFs or coming from endemic coun-
tries) and, only for hospitals where CPE were endemic (with
sustained intra-facility transmission) or where epidemic
clusters were detected during the previous year, patients
admitted to intensive care units, spinal cord injury units,
transplant units, oncology and hematology units. CPE
screening for carriers was not recommended in LTCFs.
Subsequently, the Italian Ministry of Health produced
an Act [43] for the implementation of national surveil-
lance of bloodstream infections by carbapenem resistant
Escherichia coli and Klebsiella pneumoniae. The Act
recommends active screening in all contacts of CRE-
positive patients, in all patients with a previous
colonization/infection that are admitted to hospital, and
in all patients coming from endemic areas. Moreover,
screening was suggested for patients admitted or trans-
ferred to high-risk units and in patients transferred from
another hospital or with a history of recent hospitalization
or coming from long term care facilities. Ministry of
Health recommended also contact precautions and isola-
tion for all colonized/infected individuals, including
cohorting strategies, strengthening hand hygiene proce-
dures and education.
Since CRE colonization is associated with an increased
risk of CRE infection, knowledge of CRE colonization
can be relevant not only to infection control but also to
antimicrobial stewardship. In particular, in certain cat-
egories of colonized patients who are at high-risk for in-
vasive infections (e. g. neutropenic patients), knowledge
of CRE colonization can be relevant to the selection of
empiric antimicrobial chemotherapy covering the colon-
izing pathogen in case of emergence of a septic status In
this case, knowledge of the resistance mechanism of the
colonizer is particularly important, given the different
spectrum of activity of anti-CRE agents for example, the
empirical use of ceftazidime-avibactam could be consid-
ered in case of a CPE producing KPC but not in case of
a CPE producing a metallo-β-lactamase [44].
Methods for active screening of CRE carriage
Screening for CRE colonization is usually based on micro-
biological evaluation of rectal swabs. To date there is little
evidence that swabs from alternative sites could add more
useful information, although screening from any other site
putatively colonized could be considered. The isolation of
CRE from other sites normally screened for colonization
by MDR pathogens in ICU patients (i.e. nasal swabs,
pharyngeal swabs, bronchial aspirates, urine cultures in
catheterized patients) should always be considered and
carefully evaluated in at-risk patients. CRE isolation from
any clinical site should dictate an indication for a rectal
swab, because invasive disease or colonization in the ab-
sence of intestinal carriage may represent a break in the
standard of health care workers behavior and infection
control procedures [45].
Surveillance tests to detect CRE present three main
challenges: turnaround time (TAT), sensitivity and spe-
cificity. Screening methods can be subdivided into two
major groups:
1. culture-based methods;
2. nucleic acid amplification technology (NAAT)-based
assays.
Culture-based methods for CRE screening
Culture-based methods have been widely used for CRE
screening, largely because initial testing is relatively easy
to implement, as the necessary equipment and knowledge
are already present in routine microbiology laboratories.
Several different cultural approaches have been described:
a) inoculation onto McConkey agar plate after broth
enrichment (CDC method) [46];
b) direct inoculation onto McConkey agar plate con-
taining a meropenem disk [47];
c) direct inoculation onto specific selective chromo-
genic media [48–50].
The CDC screening method addresses the need to
maximize sensitivity (detection of low-level resistance and/
or low loads of CRE), but recent reports [48, 49] showed
that other culture-based protocols have a better or at least
comparable performance. Moreover, the CDC method has
significant limitations: in particular, the TAT for a positive
or preliminary positive result is slow (48–72 h) and the
protocol is time-consuming for the laboratory workflow.
The main advantages of direct inoculation onto McCon-
key agar plate containing a meropenem disk include low
cost, ease of evaluation of suspected colonies and the pos-
sibility of checking the quality of the samples (low quality,
if no bacterial growth is observed). Some authors sug-
gested the use of a second disk, containing meropenem
and boronic acid, to rapidly discriminate the presence of
KPC-producing isolates. TAT for positive samples is typ-
ically 24–48 h. However, the need to add the meropenem
disk after inoculum represents a significant increment of
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manual workload and also a risk of contamination. A
main concern with this method is lack of sensitivity, espe-
cially for CPEs which typically show MICs to the carba-
penems at or around the breakpoint [48].
A number of selective chromogenic media have been
developed to simplify culture-based protocols [48–50].
These media usually incorporate a carbapenem as select-
ive agent and substrates resulting in color change when
hydrolyzed by Enterobacterales. Advantages of this ap-
proach include an easy workflow for inoculation and
evaluation of growth, presumptive species identification,
good sensitivity and specificity. The TAT for positive
samples is 24–48 h. However, selective media that were
specifically designed to target KPC producers have
shown low sensitivity for mechanisms due to other en-
zymes, particularly OXA-48 [51]. Moreover, selective
chromogenic media are more expensive that McConkey
agar and, when using the former media, a second non-
selective plate should ideally be inoculated in parallel to
check for the quality of the rectal swabs.
It is noteworthy that all culture-based methods only allow
the identification of CRE in general, but a positive result re-
quires further evaluation to confirm carbapenemase produc-
tion [52, 53]. The turnaround time for confirmatory testing
may range from a few minutes to 24 h, depending on the
methods chosen, with variable additional cost. Hospital in-
fection control programs can act on negative results and
preliminary positive results, pending confirmation, but it is
obvious that the final reporting time (TAT of screening +
TAT of confirmation test) could have an important impact
on infection control performance. Despite these limitations,
culture-based methods still maintain some peculiar advan-
tages. First of all, they can detect all types of CRE,
including organisms producing not previously known car-
bapenemases. Moreover cultural methods are fundamen-
tal to recover viable organisms, allowing the performing of
phenotypic antimicrobial susceptibility testing, the collec-
tion and storing of CRE strains.
NAAT for CRE screening
Molecular based methods (NAAT) for CRE screening
usually detect the presence of one or more carbapene-
mase genes. For this reason, these assays are able to
identify only previously known resistance determinants.
Reliable detection of multiple genes, as well as extrac-
tion, could represent a challenge for NAAT applied to
high-complexity samples such as stool or rectal swabs.
Another critical issue is related to the typical feature of
CPE epidemiology: since global CPE diffusion is complex
and typically shows differences between different coun-
tries, molecular assays suitable for screening use should
cover a broad spectrum of carbapenemase genes, includ-
ing at least the five most common families (KPC, VIM,
NDM, IMP, OXA-48).
Despite these difficulties, several in-house and com-
mercial molecular methods for CPE/CRE surveillance
have been developed in the last few years with the aim
to overcome most of the limitations of culture-based
methods and, in particular, to reduce TAT. NAAT-
based assays validated for carbapenemase genes detec-
tion from rectal swabs can also be used as a confirma-
tory test for suspected colonies identified by culture-
based methods, although not all commercial assays have
an on-label indication for this.
Briefly, three types of NAAT-based assays can be
taken in consideration for CPE/CRE surveillance: in
house molecular methods, commercial molecular assays,
and rapid/easy to use commercial molecular assays.
In house molecular methods can show good level of
sensitivity and specificity [54]. Moreover, these assays
are less expensive if compared to molecular commercial
methods; on the other hand, important disadvantages
are low level of automation, standardization and valid-
ation, and suboptimal inter-laboratory reproducibility.
Commercial molecular assays are highly sensitive, spe-
cific and standardized, with TAT of few hours; the level of
automation of these methods can vary from poor (need of
sample preparation step, including extraction or lysis,
and/or multiple hands-on steps), to good, but for all these
assays laboratory experience and equipment are required.
Rapid/easy to use commercial molecular assays (REU-
CMA) may provide the same high standard of quality of
results [55], with shorter hands-on time and TAT (less than
1 h) and no requirement for batching. Furthermore, these
fully automated methods can be used as point of care test-
ing, streamlining the diagnostic workflow in particular if the
microbiology lab is distant from the care structure or during
closing hours. However, coverage within carbapenemase
gene families, level of automation, turn-around time and
suitability as point of care testing widely vary between differ-
ent commercial molecular methods. It should be noted that
time to result and easiness of access to results are particu-
larly relevant issues for infection control purposes.
Currently, limitations of NAAT assays include labora-
tory acquisition costs and the ability to detect a limited
number of known carbapenemases, while the main advan-
tages are the short TAT for both negative and positive re-
sults that could positively impact at the organisational
level on infection control programmes, and the improved
sensitivity over some cultural methods. Moreover, as
noted previously, awareness of the specific carbapenemase
detected can be critical in decisions around optimal anti-
microbial therapy.
Strategies for active screening of CRE carriage in settings
of high-level endemicity
Several strategies can be considered for active screening
of CRE carriage in healthcare settings, depending on the
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organisational context of the setting and the CRE epi-
demiology in that setting and its catchment population.
Basically, the strategy must define the target patients and
the method(s) for active screening and should be inte-
grated with IPC and antimicrobial stewardship programs.
The choice of method for active CRE screening should
be agreed with the local IPC Team, taking into account
different variables (prevalence of colonization, types of
circulating carbapenemases, wards with higher incidence
and severity of infections caused by CPE, ease of isola-
tion of positive and presumptive positive patients, access
to Clinical Microbiology laboratory, overall costs). More-
over, it must be emphasized that active surveillance is
one of several interventions within the multifaceted pro-
grams for the prevention of transmission of CPE, and
the impact of active screening will depend not only on
its quality but also on its contextualization within a
complex bundle.
The most recent report of ECDC [45] about the effect-
iveness of infection control measures to prevent trans-
mission of CPE stated that no study assessed screening/
surveillance as a single intervention, but the authors
concluded that there is evidence to suggest that active
rectal screening/surveillance on admission to hospital or
a specific ward and during an outbreak can effectively
limit and prevent the spread of CPE. The ECDC docu-
ment recognizes among other most effective interven-
tions patient isolation, patient cohorting and application
of contact precautions. All these measures are usually
applied when a patient is diagnosed as colonized and/or
infected by CPE. Molecular methods for CPE surveil-
lance can reduce TAT for the detection of colonized pa-
tients by 48–72 h, compared to traditional culture-based
methods. Although there is still limited data available
regarding the impact of rapid surveillance methods in
prevention of transmission of CPE, it is likely that identi-
fication and isolation of carriers 2–3 days earlier could
lead to reduction in the transmission risk and a more ef-
ficient use of infection prevention resources. Moreover,
rapid screening methods could make it easier to adopt
the strategy of pre-emptive isolation of patients on ad-
mission until the report of a negative result, another
measure considered effective by the ECDC paper.
As suggested by Lau et al. [56] in their recent review
about CPE screening methods, the universal use of
NAAT-based assays for surveillance swabs may not be
affordable because of the increased costs, but the use of
molecular rapid methods may be advisable if applied to
the screening of high-risk patients (e. g. returning from
areas of endemicity, transferred from LTCFs, or having
had an extensive exposure to carbapenems). The au-
thors also stated that the ideal molecular assay for most
epidemiological contexts should include at least KPC,
OXA-48, NDM and VIM-encoding determinants.
Moreover, samples with negative or indeterminate re-
sults should be tested with a sensitive culture-based
method and suspected colonies should be subjected to
a confirmatory test for carbapenemase activity.
Screening for detection of CPE colonized patients is a
fundamental part of CPE infection control programs. The
optimal modality for surveillance strategy and methods
should be evaluated by each institution considering several
specific features. Culture-based screening methods can
easily be implemented by most clinical microbiology la-
boratories and still represent the fundamental backbone
of CPE active surveillance, providing the possibility to de-
tect all types of carbapenem-resistant organisms, to per-
form phenotypic susceptibility testing, to collect and store
the strains. On the other hand, long TAT (at least 24 for
positive results) could be considered suboptimal for high-
risk patients. Use of new generation of rapid-easy to use
NAAT-based assays with high levels of sensitivity, specifi-
city and very quick TAT, although still characterized by a
high direct acquisition cost, may lead to more timely de-
tection of colonized patients, thus improving the overall
performance of the CPE prevention and also reducing
costs related to hospitalization of patients with colo-
nization and/or infection caused by CPE.
Common questions about active screening for
CRE, and consensus-based recommendations
Which settings require active screening for CRE, and
which patients should be screened?
It was agreed that active screening is a cornerstone in
the control of CRE, including in high-burden settings. In
these settings, the focus needs to be on patients at high-
est risk of CRE infections and of causing transmission to
other high-risk groups. From an epidemiological point
of view, considering the current risk factor stratification,
the populations that should be targeted for CRE screen-
ing on admission to acute-care hospitals are: i) patients
admitted from long-term care and rehabilitation facil-
ities; ii) patients who are transferred directly from an-
other acute-care hospital; and iii) patients admitted from
the community with a history of hospital admission
within the last 12 months [43]. From a clinical point of
view, all patients in whom colonization could represent
a risk factor for invasive disease should be screened on
admission and then weekly during hospital stay. Severely
immunosuppressed subjects, critically ill patients and pa-
tients exposed to major surgery should be the first to be
included in a screening program. Accordingly, with this
indication, ICUs, Transplant Units, Hematological Units,
major surgical and Infectious Disease units represent the
preferential setting for targeting active screening. Con-
sidering the heavy involvement of long-term care facil-
ities in CRE dissemination in endemic settings [20, 57,
58], active screening as part of an IPC program is also
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recommended for all patients admitted to these
structures.
What is the role of REU-CMA?
Currently available CPE infection control guidelines do
not suggest which is the most appropriate method to
apply for active surveillance because of the lack of strong
evidence defining the optimal method.
Although having high acquisition costs compared to
conventional culture, REU-CMA seem an appealing
method for CPE screening, due to the fast TAT, high
sensitivity, and opportunity for information on the re-
sistance mechanism which can be relevant for the pur-
poses of IPC strategies and antimicrobial stewardship.
From the IPC point of view, the availability of REU-
CMA could provide rapid information on colonization
status, allowing to retain contact precautions only for
colonized patients and to rapidly release preemptive
contact isolation for patients who are not colonized.
This can help to reduce the risk of inter-patient spread
in high endemicity settings, due to failures to comply
with long-lasting (2–3 days) preemptive contact isolation
and can also be cost-effective by saving the resources re-
quired for long-lasting contact isolation with all new ad-
missions. The additional cost of materials, disinfection
and extra nursing time per patient due to preemptive
contact precautions for a range of antibiotic resistant or-
ganisms, has been estimated to range between 1.27 to
4.1€ per hour [59–61]. In settings with a 10% prevalence
in the high risk population, this could mean that 90% of
the patients will be unnecessarily put in preemptive con-
tact precautions waiting for the result of the screening
test at a cost between 61€ to 197€ per patient if the test
is performed using a culture-based technique. Early
identification of patients suspected of being colonized
with and CPE combined with rapid implementation of
contact precautions is the cornerstone of an efficient
IPC strategy [45]. Moreover, the rapid feed-back pro-
vided by REU-CMA can be particularly useful in the
management of outbreaks.
From a clinical point of view, REU-CMA could be very
useful to target any empirical/ pre-emptive therapeutic ap-
proach in severely ill patients at risk of CRE infection. In-
deed, a rapid recognition of the carrier status and the
characterization of the genetic pattern of resistance enables
appropriate treatment to be targeted as early as possible.
Finally, it should be noted that REU-CMA can also be
amenable to near-patient testing. This option could be
particular interest in health care settings where an on-
site clinical microbiology laboratory is not available, and
screening samples must be sent to an external facility for
processing, a situation that is often encountered in long-
term care/rehabilitation facilities. Indeed, in these cases,
implementation of a REU-CMA on-site, which can be
handled remotely by a clinical microbiologist, can save
considerable time in the identification of CRE colonized
patients that require contact isolation and dedicated re-
habilitation pathways.
The choice of inclusion criteria of the samples on which
the molecular test could eventually be used should be
shared with the local IPC Team, considering different spe-
cific local variables (prevalence of colonization, high risk
wards, possibility to apply presumptive isolation) in order
to optimize the clinical and economical impact.
How should we manage information and patients in
relation to carriage status?
At the moment of diagnosis of carrier status, it is
mandatory to give all information to the patient, the
family and the caregivers, in order to ensure that the
best practices and the proper use of personal protective
equipment during hospitalization are adhered to. On dis-
charge, all information about patient status including the
condition of CRE carrier must be reported to the general
practitioner or to the long-term care / rehabilitation struc-
ture that will receive the patient. It is necessary that all
hygienic standards are respected, and the adherence to
hand washing practices is maximized, both at home and
in long-term care facilities.
In order to prevent and reduce the spread of CRE,
general, organizational and clinical care measures need
to be put in place. For every patient admission, each
hospital must adopt a flow chart for infection prevention
and control (IP&C) of CPE. It has to set up the early rec-
ognition of individuals who may be colonized or in-
fected, organize the early isolation of suspected and
laboratory-confirmed cases and ensure early diagnosis of
suspected cases and contacts during hospitalization by
adopting a systematic screening programme.
Conclusions
Continuing transmission of CPE in Italy and a number of
other European countries remains a cause for grave con-
cern. This position paper provides information regarding
the background to the problem and a brief overview of
current guidance documents, with particular respect to the
role of active surveillance. While it is clear that active sur-
veillance for carriage of CPE remains an important aspect
of the overall “bundle approach” to containment, evidence
is scanty regarding the precise role of screening, types of
patients and clinical units to be screened, and method of
screening including the role for REU-CMA. While we have
attempted to provide some pragmatic advice on active sur-
veillance in a high burden country, we also wish to high-
light the importance of further research into this topic.
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